Hims & Hers Health has handed back a chunk of the 16% rally flagged in the prior note, falling 10.4% on the week to close at $28.44 — a sharp reversal that reopens the question of whether that move was genuine demand or simply short covering running its course.
The positioning data tells a nuanced story. Short interest has continued its gradual drift lower, now at 26.4% of the free float — around 57.8 million shares — down roughly 3% on the week and 5% over the past month. That direction of travel hasn't changed from the prior note; what has changed is the pace of loosening in the borrow market. Availability has actually improved further, rising to 75.6% from around 58-62% a week ago, and cost to borrow has fallen to 0.59% — its lowest level in the 30-day window and well below the 0.8-0.9% range that held through most of August. The message from the lending market is that shorts are not scrambling; borrow is cheap and plentiful. Options, meanwhile, are offering no alarm signal. The put/call ratio sits at 0.57, fractionally below its 20-day average of 0.57 and essentially a flat z-score — unremarkable, and a long way from the elevated hedging demand seen earlier this month. Taken together, the positioning landscape looks neither aggressively short nor defensively positioned; it reads more like a pause than a conviction trade.
The Street's reaction to the week's weakness is arguably the most telling frame. After the August 10 earnings print — which saw the stock fall 3.4% the next day and 9.4% over five sessions — analysts clustered around cautious upgrades rather than bold re-ratings. Morgan Stanley raised its target from $21 to $28 while keeping Equal-Weight. BofA lifted to $32, staying Neutral. Truist, raising to $32 most recently on August 24, also held at Hold. Only Needham at $42 (Buy) and Barclays at $35 (Overweight, albeit trimmed from $39) carry genuinely positive ratings. The consensus mean target of $31.23 now sits almost exactly at current price, meaning the Street collectively has essentially no upside pencilled in from here. Factor scores reinforce the caution: EPS surprise ranks in the 2nd percentile, EPS momentum over 30 days in the 7th — the recent beats are not flowing through to positive revision momentum. The EV/EBITDA of 21.9x has compressed modestly over 30 days, but PE has re-rated sharply higher, up more than 10 points on the month to 34.6x, as earnings estimates have lagged the stock's volatile swings.
The CEO's presence on the 13D register is worth flagging. Andrew Dudum filed a Schedule 13D/A on August 31 — the activist designation applies — and his disclosed stake has declined from 10.3% to 9.4%, with recent institutional data showing a reduction of nearly 1.4 million shares. The 13D classification means Dudum retains the capacity to engage actively with the company, but the direction of his disclosed position is toward trimming, not building. As always, 13D/G stakes are event-driven disclosures; a holder can exit further without filing until they breach thresholds. BlackRock, the largest institutional holder at 12.3%, added 2.4 million shares in its most recent reported period — a constructive signal from the passive side, though insufficient on its own to anchor sentiment.
The ORTEX short score of 70.3 has been remarkably stable across the past two weeks, holding in a narrow 69.5-71.0 band. That persistence — even as the stock swung 16% up and then 10% back — suggests the underlying short thesis has not been dislodged. With the next earnings event not due until November 2, the near-term focus narrows to whether the borrow market's continued loosening reflects waning short conviction, or simply reflects that shorts are comfortable holding at current cost. The $28-$32 range — bounded below by the stock's recent lows and above by the analyst consensus — is worth watching as the primary battleground into month-end.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
